Korea Investment Corp Regenxbio Inc. Transaction History

Korea Investment Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$30.19 - $40.28 $11.9 Million - $15.8 Million	-393,071 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$29.09 - $45.68 $1.83 Million - $2.87 Million	-62,900 Reduced 13.79%	393,071 $16.5 Million
Q2 2021 Aug 12, 2021	SELL	$32.46 - $40.48 $386,274 - $481,711	-11,900 Reduced 2.54%	455,971 $17.7 Million
Q1 2021 May 13, 2021	SELL	$33.61 - $49.95 $742,781 - $1.1 Million	-22,100 Reduced 4.51%	467,871 $16 Million
Q4 2020 Feb 10, 2021	BUY	$26.52 - $49.35 $1.17 Million - $2.19 Million	44,300 Added 9.94%	489,971 $22.2 Million
Q3 2020 Nov 12, 2020	SELL	$27.01 - $40.26 $1.33 Million - $1.99 Million	-49,400 Reduced 9.98%	445,671 $12.3 Million
Q2 2020 Aug 12, 2020	BUY	$27.75 - $43.44 $210,900 - $330,144	7,600 Added 1.56%	495,071 $18.2 Million
Q1 2020 May 14, 2020	BUY	$21.5 - $54.2 $685,850 - $1.73 Million	31,900 Added 7.0%	487,471 $15.8 Million
Q4 2019 Feb 11, 2020	BUY	$34.54 - $44.87 $607,904 - $789,712	17,600 Added 4.02%	455,571 $18.7 Million
Q3 2019 Nov 12, 2019	BUY	$31.84 - $50.88 $1.13 Million - $1.81 Million	35,500 Added 8.82%	437,971 $15.6 Million
Q2 2019 Aug 12, 2019	BUY	$42.0 - $59.29 $16.9 Million - $23.9 Million	402,471 New	402,471 $20.7 Million

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $420M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Korea Investment Corp, based on Form 13F filings with the SEC.

Stay updated on Korea Investment Corp with notifications on news.